Oxidative StressPhase 2NCT04732247
Oxytocin for Oxidative Stress and Inflammation
A Phase 2 study testing Oxytocin nasal spray in people with Oxidative Stress and Inflammation, run by Florida Institute for Human and Machine Cognition at 3 sites in United States.
Trial summary
Naval Special Warfare (NSW) operators are exposed to a variety of extreme environmental conditions and intense physical demands. In addition to breathing high pressure gases at depth, prolonged cold water immersion and inadequate recovery from sustained physical exertion negatively impact individual and team… Read more about this study
- Who is it for?
- Ages 18 to 39 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Oxidative Stress, Inflammation
- What is being tested?
- Oxytocin nasal spray
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 3 sitesUnited States
- Study dates
- 1 Feb 2022to 15 Sep 2023
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 39 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Apparently healthy (assessed via health, activity, and medical history)
- BMI < 30
- No chronic conditions that would preclude participation
- Recreationally skilled swimmer capable of a continuous 30 min kickboard swim
Who cannot join
- Regular smoking. The smoking exclusion includes all forms (cigarettes, vaping, etc) due to well-established effects on lung function and systemic oxidative stress and inflammation
Trial locations and contacts
3 sites in 1 country.
United States3 sites
University of Florida
Gainesville, Florida, 32611
Florida Institute for Human and Machine Cognition
Pensacola, Florida, 32502
Translational Genomics Research Institute
Phoenix, Arizona, 85004
About this study
Official title: Evaluating Potential Benefits of Intranasal Oxytocin on Undersea Operator Training and Performance: Hyperoxic Swim-Induced Oxidative Stress and Inflammation
Naval Special Warfare (NSW) operators are exposed to a variety of extreme environmental conditions and intense physical demands. In addition to breathing high pressure gases at depth, prolonged cold water immersion and inadequate recovery from sustained physical exertion negatively impact individual and team performance. Biotechnologies that could mitigate the effects of cold as well as support physical recovery represent a significant unmet need for the NSW operational community.
Oxytocin (OT) has a wide range of actions both locally in the brain and peripherally in the body including skeletal muscle. These peripheral effects can be mediated by classic ligand-receptor activation given the abundant expression of the oxytocin receptor in peripheral tissues, along with local expression of OT in peripheral tissues where it is likely to act in an autocrine manner. Exogenous OT via intranasal administration is FDA Investigational New Drug (IND)-approved and has been demonstrated as an easy and safe method to increase circulating OT concentrations that may augment actions on peripheral tissues.
Due to the pleiotropic effects of OT on whole body metabolism, thermogenesis, stress responses, pain, mood, inflammation, appetite, glycemic control, skeletal homeostasis, and skeletal muscle repair and regeneration, there is increasing interest in the administration of exogenous OT for benefits to human health, performance and resilience. However, the biological mechanisms by which OT exerts tissue-specific effects (e.g., skeletal muscle) remain poorly understood, particularly in humans. This project is designed to significantly advance this understanding while testing the central hypothesis that intranasally administered OT attenuates systemic and skeletal muscle oxidative stress and inflammation induced by the combined stressor of resistance swim exercise and hyperoxia.
Read the detailed description
Naval Special Warfare (NSW) operators are exposed to a variety of extreme environmental conditions and intense physical demands. In addition to breathing high pressure and hyperoxic gases at depth, prolonged cold water immersion and inadequate recovery from sustained physical exertion negatively impact individual and team performance. Biotechnologies that could mitigate the effects of these extreme conditions as well as support physical recovery represent a significant unmet need for the NSW operational community.
Oxytocin (OT) has a wide range of actions both locally in the brain and peripherally including skeletal muscle and a number of peripheral targets. OT may attenuate acute cardiovascular stress responses, while chronic OT exposure may reduce risk of CVD and other chronic diseases via anti-inflammatory effects and attenuation of mitochondrial oxidative stress. These effects can be mediated by classic ligand-receptor activation given the abundant expression of the oxytocin receptor in peripheral tissues, along with local expression of OT in peripheral tissues where it is likely to act in an autocrine manner. Exogenous OT via intranasal administration is FDA Investigational New Drug (IND)-approved and has been demonstrated as an easy and safe method to increase circulating OT concentrations that may augment actions on peripheral tissues.
Due to the pleiotropic effects of OT on whole body metabolism, thermogenesis, stress responses, pain, mood, inflammation, appetite, glycemic control, skeletal homeostasis, and skeletal muscle repair and regeneration, there is increasing interest in the administration of exogenous OT for benefits to human health, performance and resilience. However, the biological mechanisms by which OT exerts tissue-specific effects (e.g., skeletal muscle) remain poorly understood, particularly in humans.
This project is designed to significantly advance this understanding while testing the central hypothesis that intranasally administered OT attenuates systemic and skeletal muscle oxidative stress and inflammation induced by the combined stressor of resistance swim exercise and hyperoxia. If efficacy is demonstrated, the ultimate deliverable would be an easily administered, adjunctive biological therapy expected to improve performance and resilience of undersea warfighters. The planned project will extend current IHMC research focused on developing biotechnologies to enhance human performance and resilience. The central hypothesis will be tested via two specific aims - using a rigorous, double-blind, placebo-controlled, randomized trial leveraging a wash-in design, enrolling N=40 18-39 y/o men.
Specific Aim 1. To investigate the efficacy of intranasal OT on attenuating systemic and skeletal muscle oxidative stress and inflammation induced by the combined stressor of intensive, resistance swim exercise and hyperoxia. Participants will be randomly assigned with a 1:1 distribution to 48 IU intranasal OT vs. placebo (saline). Investigators will test the effects of 4x per day (QID) intranasal treatment on performance and the acute inflammatory and oxidative stress responses to resistance swimming under hyperoxia, along with the timecourse of recovery over 48 h. To assess blood and muscle oxidative stress investigators will measure antioxidant enzymes, along with markers of oxidative stress-induced DNA damage, protein carbonylation, and lipid peroxidation. Systemic inflammation will be assessed via a 7-plex serum cytokine array, and muscle inflammation will be assessed via the TNF-a and IL-6 signaling pathways.
Specific Aim 2. To leverage proven molecular mapping strategies to identify key molecular transducers likely driving any effects of intranasal OT on systemic and muscle oxidative stress and inflammation throughout 48 h of recovery. Given the paucity of data on mechanisms by which exogenous OT exerts its effects, the investigators will take a discovery approach to identify novel molecular networks and pathways that are differentially regulated by OT vs. placebo during recovery from an intensive, resistance swim exercise under hyperoxia. To accomplish this the investigators will perform multi-level modeling that integrates data from metabolomics, transcriptomics (both long and small RNA sequencing from blood plasma and muscle), and miRNA sequencing of circulating extracellular vesicles (EVs).
If intranasal OT demonstrates efficacy, the deliverable would be an adjunctive biological therapy that mitigates oxidative stress as well as enhances performance during and recovery from resistance swimming under hyperoxia.
- Conditions
- Oxidative Stress, Inflammation
- Being tested
- Oxytocin nasal spray, Placebo nasal spray
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oxytocin nasal sprayDrug
Also called Oxytocin
Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
Placebo nasal sprayDrug
Also called Placebo
Intranasal treatment with placebo via nasal spray
| Study group | Role | What they receive |
|---|---|---|
| Oxytocin nasal spray | Experimental | 4x per day (QID) intranasal treatment with oxytocin (48 IU per dose) Receives: Drug: Oxytocin nasal spray |
| Placebo nasal spray | Placebo comparator | 4x per day (QID) intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin) Receives: Drug: Placebo nasal spray |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in muscle oxidative stress via glutathione reductase activity
Change in muscle glutathione reductase enzyme activity assessed by measuring muscle tissue levels of the reduced product, glutathione (GSH)
Measured: Change in muscle glutathione reductase activity from before to 3 hours after the resistance swim + hyperoxia
Change in blood oxidative stress via glutathione reductase activity
Change in blood glutathione reductase enzyme activity assessed by measuring blood levels of the reduced product, glutathione (GSH)
Measured: Change in blood glutathione reductase activity from before to 3 hours after the resistance swim + hyperoxia
Secondary outcomes (1)
Change in systemic inflammation via serum concentration of interleukin-6 (IL-6)
Change in systemic inflammation via serum concentration (pmol) of interleukin-6 (IL-6) assessed by enzyme-linked immunosorbent assay (ELISA)
Measured: Change in serum IL-6 concentration from before to 3 hours after the resistance swim + hyperoxia
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Feb 2021
- Study start1 Feb 2022
- Primary completion15 Sep 2023
- Study completion15 Sep 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oxidative StressStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double-blind, placebo-controlled, randomized trial leveraging a wash-in design
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Florida Institute for Human and Machine Cognition
- Sponsor type
- University, hospital or other
- Collaborators
- Office of Naval Research (ONR), University of Florida, University of Alabama at Birmingham, Translational Genomics Research Institute
- Responsible party
- Sponsor
- Investigators
- Marcas M Bamman, PhD, Principal investigator, Florida Institute for Human & Machine Cognition
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04732247
- Sponsor's protocol ID
- IRB-2020-0000
- Status last verified
- Jun 2023
- First submitted
- 6 Jan 2021
- Last updated
- 22 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: No IPD sharing planned
Study at a glance
From the registry record, last updated by the sponsor on 22 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating Potential Benefits of Intranasal Oxytocin on Undersea Operator Training and Performance: Hyperoxic Swim-Induced Oxidative Stress and Inflammation
- ClinicalTrials.gov ID
- NCT04732247
- Acronym / sponsor ID
- IRB-2020-0000
- Conditions
- Oxidative Stress, Inflammation
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Florida Institute for Human and Machine CognitionUniversity, hospital or other
- Collaborators
- Office of Naval Research (ONR), University of Florida, University of Alabama at Birmingham, Translational Genomics Research Institute
- Study start
- 1 Feb 2022 (actual)
- Primary completion
- 15 Sep 2023 (actual)
- Study completion
- 15 Sep 2023 (actual)
- First posted
- 1 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Naval Special Warfare (NSW) operators are exposed to a variety of extreme environmental conditions and intense physical demands. In addition to breathing high pressure gases at depth, prolonged cold water immersion and inadequate recovery from sustained physical exertion negatively impact individual and team performance. Biotechnologies that could mitigate the effects of cold as well as support physical recovery represent a significant unmet need for the NSW operational community.
Oxytocin (OT) has a wide range of actions both locally in the brain and peripherally in the body including skeletal muscle. These peripheral effects can be mediated by classic ligand-receptor activation given the abundant expression of the oxytocin receptor in peripheral tissues, along with local expression of OT in peripheral tissues where it is likely to act in an autocrine manner. Exogenous OT via intranasal administration is FDA Investigational New Drug (IND)-approved and has been demonstrated as an easy and safe method to increase circulating OT concentrations that may augment actions on peripheral tissues.
Due to the pleiotropic effects of OT on whole body metabolism, thermogenesis, stress responses, pain, mood, inflammation, appetite, glycemic control, skeletal homeostasis, and skeletal muscle repair and regeneration, there is increasing interest in the administration of exogenous OT for benefits to human health, performance and resilience. However, the biological mechanisms by which OT exerts tissue-specific effects (e.g., skeletal muscle) remain poorly understood, particularly in humans. This project is designed to significantly advance this understanding while testing the central hypothesis that intranasally administered OT attenuates systemic and skeletal muscle oxidative stress and inflammation induced by the combined stressor of resistance swim exercise and hyperoxia.
Detailed description
Naval Special Warfare (NSW) operators are exposed to a variety of extreme environmental conditions and intense physical demands. In addition to breathing high pressure and hyperoxic gases at depth, prolonged cold water immersion and inadequate recovery from sustained physical exertion negatively impact individual and team performance. Biotechnologies that could mitigate the effects of these extreme conditions as well as support physical recovery represent a significant unmet need for the NSW operational community.
Oxytocin (OT) has a wide range of actions both locally in the brain and peripherally including skeletal muscle and a number of peripheral targets. OT may attenuate acute cardiovascular stress responses, while chronic OT exposure may reduce risk of CVD and other chronic diseases via anti-inflammatory effects and attenuation of mitochondrial oxidative stress. These effects can be mediated by classic ligand-receptor activation given the abundant expression of the oxytocin receptor in peripheral tissues, along with local expression of OT in peripheral tissues where it is likely to act in an autocrine manner. Exogenous OT via intranasal administration is FDA Investigational New Drug (IND)-approved and has been demonstrated as an easy and safe method to increase circulating OT concentrations that may augment actions on peripheral tissues.
Due to the pleiotropic effects of OT on whole body metabolism, thermogenesis, stress responses, pain, mood, inflammation, appetite, glycemic control, skeletal homeostasis, and skeletal muscle repair and regeneration, there is increasing interest in the administration of exogenous OT for benefits to human health, performance and resilience. However, the biological mechanisms by which OT exerts tissue-specific effects (e.g., skeletal muscle) remain poorly understood, particularly in humans.
This project is designed to significantly advance this understanding while testing the central hypothesis that intranasally administered OT attenuates systemic and skeletal muscle oxidative stress and inflammation induced by the combined stressor of resistance swim exercise and hyperoxia. If efficacy is demonstrated, the ultimate deliverable would be an easily administered, adjunctive biological therapy expected to improve performance and resilience of undersea warfighters. The planned project will extend current IHMC research focused on developing biotechnologies to enhance human performance and resilience. The central hypothesis will be tested via two specific aims - using a rigorous, double-blind, placebo-controlled, randomized trial leveraging a wash-in design, enrolling N=40 18-39 y/o men.
Specific Aim 1. To investigate the efficacy of intranasal OT on attenuating systemic and skeletal muscle oxidative stress and inflammation induced by the combined stressor of intensive, resistance swim exercise and hyperoxia. Participants will be randomly assigned with a 1:1 distribution to 48 IU intranasal OT vs. placebo (saline). Investigators will test the effects of 4x per day (QID) intranasal treatment on performance and the acute inflammatory and oxidative stress responses to resistance swimming under hyperoxia, along with the timecourse of recovery over 48 h. To assess blood and muscle oxidative stress investigators will measure antioxidant enzymes, along with markers of oxidative stress-induced DNA damage, protein carbonylation, and lipid peroxidation. Systemic inflammation will be assessed via a 7-plex serum cytokine array, and muscle inflammation will be assessed via the TNF-a and IL-6 signaling pathways.
Specific Aim 2. To leverage proven molecular mapping strategies to identify key molecular transducers likely driving any effects of intranasal OT on systemic and muscle oxidative stress and inflammation throughout 48 h of recovery. Given the paucity of data on mechanisms by which exogenous OT exerts its effects, the investigators will take a discovery approach to identify novel molecular networks and pathways that are differentially regulated by OT vs. placebo during recovery from an intensive, resistance swim exercise under hyperoxia. To accomplish this the investigators will perform multi-level modeling that integrates data from metabolomics, transcriptomics (both long and small RNA sequencing from blood plasma and muscle), and miRNA sequencing of circulating extracellular vesicles (EVs).
If intranasal OT demonstrates efficacy, the deliverable would be an adjunctive biological therapy that mitigates oxidative stress as well as enhances performance during and recovery from resistance swimming under hyperoxia.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Double-blind, placebo-controlled, randomized trial leveraging a wash-in design
| Arm | Type | Receives |
|---|---|---|
| Oxytocin nasal spray | Experimental | Drug: Oxytocin nasal spray4x per day (QID) intranasal treatment with oxytocin (48 IU per dose) |
| Placebo nasal spray | Placebo comparator | Drug: Placebo nasal spray4x per day (QID) intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin) |
Who may qualify
- Ages
- 18 to 39 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Apparently healthy (assessed via health, activity, and medical history)
- BMI < 30
- No chronic conditions that would preclude participation
- Recreationally skilled swimmer capable of a continuous 30 min kickboard swim
Key exclusion criteria (1 listed)
- Regular smoking. The smoking exclusion includes all forms (cigarettes, vaping, etc) due to well-established effects on lung function and systemic oxidative stress and inflammation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oxytocin nasal sprayAlso: OxytocinIntranasal treatment with oxytocin via nasal spray (48 IU per dose) | Drug | Oxytocin nasal spray |
| Placebo nasal sprayAlso: PlaceboIntranasal treatment with placebo via nasal spray | Drug | Placebo nasal spray |
Primary outcome
Change in muscle oxidative stress via glutathione reductase activity
Time frame: Change in muscle glutathione reductase activity from before to 3 hours after the resistance swim + hyperoxia
Change in muscle glutathione reductase enzyme activity assessed by measuring muscle tissue levels of the reduced product, glutathione (GSH)
Change in blood oxidative stress via glutathione reductase activity
Time frame: Change in blood glutathione reductase activity from before to 3 hours after the resistance swim + hyperoxia
Change in blood glutathione reductase enzyme activity assessed by measuring blood levels of the reduced product, glutathione (GSH)
1 secondary outcome
Change in systemic inflammation via serum concentration of interleukin-6 (IL-6)
Time frame: Change in serum IL-6 concentration from before to 3 hours after the resistance swim + hyperoxia
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Feb 2024.
- Individual participant dataSharing planned: No. No IPD sharing planned
Related trials for Oxidative Stress
RecruitingPhase 1
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC)
RecruitingObservational study
Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease
Gaucher Disease Type I, Oxidative Stress
Active, not recruitingObservational study
Role of ROS and cAMP-PKA Biomarkers in ADPKD
Autosomal Dominant Polycystic Kidney Disease
Active, not recruiting
Efficacy of MAGNESIO TOTAL on Sleep Quality and Quality of Life in Adults
Sleep Quality, Magnesium Deficiency
Active, not recruitingPhase 2
Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH
Pulmonary Hypertension of Newborn, Diaphragm Defect
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marcas M Bamman, PhD principal investigator
Florida Institute for Human & Machine Cognition
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Oxytocin nasal spray in people with Oxidative Stress and Inflammation, run by Florida Institute for Human and Machine Cognition at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in muscle oxidative stress via glutathione reductase activity (time frame: Change in muscle glutathione reductase activity from before to 3 hours after the resistance swim + hyperoxia). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Feb 2024.